Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Expanded access is currently available for this treatment.
Verified March 2016 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01947608
First received: September 17, 2013
Last updated: March 29, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: Expanded access is currently available for this treatment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given